By Finance Pulse in stock target —

Wedbush Rates Rocket Pharmaceuticals Outperform with $32 Target

Wedbush initiates coverage on Rocket Pharmaceuticals (RCKT) with an Outperform rating and a $32 price target, signaling strong growth potential.

An aesthetically pleasing graphic showcasing Rocket Pharmaceuticals' logo with an upward trend arrow
Wedbush Rates Rocket Pharmaceuticals Outperform with $32 Target

Wedbush initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target.

Source